^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CB-011

    i
    Other names: CB-011
    Company:
    Caribou Biosci
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    3ms
    High-specificity CRISPR-mediated genome engineering in anti-BCMA allogeneic CAR T cells suppresses allograft rejection in preclinical models. (PubMed, Cancer Immunol Res)
    CB-011 cells were protected from natural killer (NK) cell-mediated cytotoxicity in vitro and in vivo due to endogenous promoter-driven expression of B2M-HLA-E. Potent antitumor efficacy, when combined with an immune-cloaking armoring strategy to dampen allograft rejection, offers optimized therapeutic potential in multiple myeloma.
    Preclinical • Journal • CAR T-Cell Therapy • IO biomarker
    |
    B2M (Beta-2-microglobulin) • HLA-E (Major Histocompatibility Complex, Class I, E)
    |
    B2M elevation
    |
    CB-011
    over1year
    CB-011, a BCMA-Specific Allogeneic CAR-T Cell Therapy, Engineered with Next-Generation CRISPR Technology to Express an HLA-E Fusion Transgene to Prevent Immune Cell-Mediated Rejection, for r/r Multiple Myeloma (TCT-ASTCT-CIBMTR 2023)
    These studies support the safety and efficacy profiles of CB-011 for an upcoming first-in-human phase 1 clinical trial evaluating these allogeneic BCMA-specific CAR-T cells in patients with r/r MM.
    CAR T-Cell Therapy • IO biomarker • Immune cell
    |
    CD19 (CD19 Molecule) • B2M (Beta-2-microglobulin) • HLA-E (Major Histocompatibility Complex, Class I, E)
    |
    B2M elevation
    |
    CB-011